Aytu Biopharma (AYTU) Non-Current Assets (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Non-Current Assets data on file, last reported at $44.4 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $44.4 million, down 14.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $44.4 million (down 14.17% YoY), and the FY2025 annual result was $45.0 million, down 19.94% from the prior year.
• Non-Current Assets fell to $44.4 million in Q1 2026 per AYTU's latest filing, from $45.8 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $90.9 million in Q1 2022 and troughed at $43.9 million in Q3 2025.
• A 5-year average of $60.2 million and a median of $57.7 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets sank 51.57% in 2022, then declined 10.47% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $70.8 million in 2022, then decreased by 15.46% to $59.9 million in 2023, then decreased by 11.2% to $53.2 million in 2024, then declined by 13.94% to $45.8 million in 2025, then decreased by 3.05% to $44.4 million in 2026.
• Business Quant data shows AYTU's Non-Current Assets at $44.4 million in Q1 2026, $45.8 million in Q4 2025, and $43.9 million in Q3 2025.